STX vs. MXC, PXS, CHLL, INHC, BELL, ABDX, SAR, KNB, IMM, and PRM
Should you be buying Shield Therapeutics stock or one of its competitors? The main competitors of Shield Therapeutics include Argent BioPharma (MXC), Provexis (PXS), Chill Brands Group (CHLL), Induction Healthcare Group (INHC), Belluscura (BELL), Abingdon Health (ABDX), Sareum (SAR), Kanabo Group (KNB), ImmuPharma (IMM), and Proteome Sciences (PRM). These companies are all part of the "medical" sector.
Shield Therapeutics (LON:STX) and Argent BioPharma (LON:MXC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
Shield Therapeutics has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Argent BioPharma has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.
Shield Therapeutics received 215 more outperform votes than Argent BioPharma when rated by MarketBeat users.
15.7% of Shield Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Argent BioPharma shares are held by institutional investors. 56.3% of Shield Therapeutics shares are held by insiders. Comparatively, 8.2% of Argent BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Shield Therapeutics' average media sentiment score of 1.53 beat Argent BioPharma's score of 0.00 indicating that Shield Therapeutics is being referred to more favorably in the media.
Argent BioPharma's return on equity of 0.00% beat Shield Therapeutics' return on equity.
Argent BioPharma has lower revenue, but higher earnings than Shield Therapeutics. Argent BioPharma is trading at a lower price-to-earnings ratio than Shield Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Shield Therapeutics beats Argent BioPharma on 8 of the 12 factors compared between the two stocks.
Get Shield Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shield Therapeutics Competitors List
Related Companies and Tools
